REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients "REGENESIS"

Withdrawn

Phase 2 Results N/A

Summary of Purpose

To assess the safety and tolerability of NTx™-265 when given to acute ischemic stroke patients. To assess the neurological outcome in acute ischemic stroke patients treated with NTx™-265, when compared with patients given a placebo control.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 2 September 2011.

1 Aug 2009 9 Jul 2008 1 Jun 2010 1 Sep 2010 1 Sep 2011 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions See All

Conditions

Sponsors

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Investigator)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment

Contacts

Not available